Abstract
Nifedipine increases the frequency and severity of gingival hyperplasia associated with CyA therapy in renal transplant recipients and this effect appears to be independent of whole-blood CyA levels. De novo malignancies have been reported arising in areas of gingival hyperplasia, in a group already at high risk of malignancy. Patients receiving CyA and nifedipine should receive advice regarding the need for strict oral hygiene to control the initial development of gingival hyperplasia, with severe cases being promptly referred for gingivectomy and histological examination.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Calcium Channel Blockers / adverse effects
-
Cyclosporine / adverse effects*
-
Cyclosporine / blood
-
Drug Interactions
-
Gingival Hyperplasia / chemically induced*
-
Gingival Hyperplasia / classification
-
Gingival Hyperplasia / prevention & control
-
Gingivectomy
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / blood
-
Kidney Transplantation / immunology*
-
Nifedipine / adverse effects*
-
Oral Hygiene
Substances
-
Calcium Channel Blockers
-
Immunosuppressive Agents
-
Cyclosporine
-
Nifedipine